Dow, Roquette Frères and JRS Pharma are Dominating the Global Excipients Market in 2020

Global Excipients Market is expected to grow with the CAGR of 6.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-excipients-market

Global excipients market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global excipients market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance,

  • In December 2018, the four U.S. sites of Dow had received EXCiPACT certificate from SGS that helped them to supply pharmaceutical excipients in the U.S. This has also increased the revenue of the company and delivered a linear growth in the market.

Dow is a dominating player in global excipients market. The other key players existing in the market includes Roquette Frères, JRS PHARMA, Evonik Industries AG, The Lubrizol Corporation (A Subsidiary of Berkshire Hathaway Inc.), BASF SE, Ashland, Kerry Group PLC, Shin-Etsu Chemical Co., Ltd., Colorcon, Chemische Fabrik Budenheim, Peter Greven GmbH & Co. KG, ADM, Croda International Plc, BENEO, Avantor, Inc, Omya AG, DFE Pharma, Pfanstiehl, Inc., MEGGLE Group Wasserburg among others.

Excipients Market

Dow

Dow was founded in 1897, has it base headquarters in Michigan, the U.S. The company is focused on becoming the most innovative, customer-centric, inclusive and sustainable science company in the world. The company deals in Surfactants, Emulsifiers and Polyglycols, Chelating Agent. The company has business segment such as Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure and Performance Materials & Coatings. The company has presence in North America. Europe, South America, Asia Pacific. The company has its base subsidiaries in Rohm and Haas (U.S.), Dow Corning (U.S.), Dow Chemical Korea Ltd (Korea), Mycogen Seeds (U.S.), Dow Global Technologies (U.S.) among others. For instance,

  • In December 2018, Dow reported that the 2020 annual meeting of shareholders will be held online by looking at the COVID-19 scenario and in the interest of health and safety of its shareholders, directors, officers and employees. This will help in creating and discussing strategies for the coming year.

Roquette Frères

Roquette Frères is headquartered in Lestrem, France and was founded in 1933. The company is a global leader in plant-based ingredients, a pioneer of plant-proteins and a leading provider of pharmaceutical excipients. The company has multiple product categories such as Bio Pharma, Pharma and Nutraceuticals, Cosmetics, Food and Nutrition, Animal Nutrition, Industrial Markets out of which Pharma and Nutraceuticals are the market focused category. The company has wide global presence across North America, South America, Europe, and Asia-Pacific.

  • In September 2020, Roquette Frères had entered into a partnership with Barentz for pharmaceuticals distribution in the U.S. Both these companies are working in European markets creating distribution channel. This partnership would increase product portfolio of the company.

JRS Pharma

JRS Pharma is headquartered in Rosenberg, Germany was founded in year 1878. The company is engaged in manufacture of excipients and offers a complete portfolio of solutions for the global health Science Industry. The company offers wide range of product categories such as Excipients and Coating. The market focused category is Excipients and Coating. The company has wide global presence across the world in North America, Europe, Asia-Pacific, Middle East and Africa, South America, Oceania. For instance,

  • In October 2020, JRS Pharma had declared that their product VIVAPHARM would be available worldwide. These are natural polymers used for coatings. This will help in increasing revenue and product portfolio of the company